Callan JMB Inc. disclosed an insider purchase by Chief Medical Officer Croyle David J, who acquired 14,805 shares of the company’s common stock on March 6, 2026. The shares were purchased at $1.762 apiece, resulting in a total transaction value of $26,086. The transaction was reported on a Form 4 filing with the Securities and Exchange Commission and was executed indirectly through a Rollover IRA.
The purchase increased Croyle’s total holdings in Callan JMB to 789,805 shares. The trade occurs while the company’s shares are trading near a 52-week low of $1.08 and reflect a 62% decline in the stock price over the past year.
Market valuation context from InvestingPro included in the company disclosure indicates a Fair Value estimate of $2.19 for CJMB. The platform also notes it provides nine additional ProTips for investors seeking further analysis of the company.
In a separate operational development, Callan JMB announced a strategic agreement with Biostax Corp, which operates under the name Attune Biotech Inc. Under the terms disclosed, Callan JMB will oversee Attune’s manufacturing and deployment operations. The scope of that role includes ensuring compliance with federal standards such as BARDA contract compliance and FDA audit readiness, and coordinating Strategic National Stockpile deployment for Attune’s therapeutic pipeline.
Callan JMB also completed its virtual annual meeting of shareholders. At the meeting, shareholders elected five directors to serve one-year terms and approved the appointment of Rosenberg Rich Baker Berman, P.A. as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Approximately 68.60% of the outstanding shares entitled to vote were represented at the meeting, either virtually or by proxy.
These developments combine an insider equity purchase, an expanded operational role in manufacturing and deployment for a partner biotech, and routine governance actions. Collectively, the items reflect activity on multiple fronts for Callan JMB as it manages ownership changes, compliance responsibilities tied to federal programs, and standard corporate governance matters.
Available information in the filings and company disclosures establishes the transactions and corporate actions described here. Where additional detail is not provided in those disclosures, such limitations are noted and no further inference is made.